专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

2. 发明申请

US20090176245A1 Rheumatoid Arthritis Test Method and Treating Method 审中-公开
标题翻译：类风湿关节炎测试方法及治疗方法
公开(公告)号：US20090176245A1
公开(公告)日：2009-07-09
申请号：US12281191
申请日：2007-03-01
申请人： Masahiko Suzuki , Fumie Aosai , Koichi Ueno
发明人： Masahiko Suzuki , Fumie Aosai , Koichi Ueno
IPC分类号： G01N33/53
CPC分类号： G01N33/564 , C07K16/18 , G01N2800/102 , G01N2800/52 , G01N2800/56
摘要： It is intended to evaluate the prognosis of rheumatoid arthritis based on the evaluation of the disease severity of the patient to select a treatment method suitable for each rheumatoid arthritis patients, and to measure HSC71 protein levels of the patients before and after the administrations of therapeutic agents to determine the efficacy of various therapeutic agents for each of rheumatoid arthritis patients, and to use thereof as a remedy for preventing onset and progression of rheumatoid arthritis. It has been revealed that whether HSC71 (heat shock cognate protein 71), which is a member of the heat shock protein 70 family, shows any difference in expression between rheumatoid arthritis patients and healthy subjects. In the case where the HSC71 protein is accelerated in a rheumatoid arthritis patient the HSC71 concentrations in the serum, synovial fluid, serebrospinal fluid, urine, saliva and sputum of the patient are measured to thereby examine the disease severity of rheumatoid arthritis. Based thereon, the prognosis of the rheumatoid arthritis is evaluated and a method suitable for the patient is selected. HSC71 protein levels are measured before and after the administration of therapeutic agents to a rheumatoid arthritis patient and the efficacy of the therapeutic agents are determined. Further, Use as a remedy or preventing the onset and progression of rheumatoid arthritis is intended.
摘要翻译：旨在通过评估患者的疾病严重程度来评估类风湿性关节炎的预后，以选择适合于每种类风湿性关节炎患者的治疗方法，并测量治疗剂施用前后患者的HSC71蛋白水平以确定各种治疗剂对于类风湿关节炎患者的功效，并将其用作预防类风湿性关节炎发病和进展的补救措施。已经显示，作为热休克蛋白70家族的成员的HSC71（热休克同源蛋白71）是否表现出类风湿性关节炎患者和健康受试者之间的表达的任何差异。在HSC71蛋白在类风湿关节炎患者中加速的情况下，测量患者血清，滑液，脊髓液，尿液，唾液和痰中的HSC71浓度，从而检测类风湿性关节炎的疾病严重程度。基于此，评估类风湿性关节炎的预后，并选择适合于患者的方法。在向类风湿性关节炎患者施用治疗剂之前和之后测量HSC71蛋白水平，并测定治疗剂的功效。此外，意图是用作补救剂或预防类风湿性关节炎的发作和进展。

IPRDB

热门服务

关于我们

友情链接

联系方式